Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kampmann

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cardiovascular Surgery (London, England)|January 25, 2003
The Fontan-operation: from intra- to extracardiac procedureW Kuroczynski, C Kampmann, Y-H Choi, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 18, 2005
The right ventricle in Fabry diseaseC Kampmann, F A Baehner, C Whybra, et al.
Zeitschrift Fur Kardiologie|August 23, 2001
[Treatment of supravalvular pulmonary stenosis after arterial switch operations (ASO)]W Kuroczynski, C Kampmann, Y H Choi, et al.
European Journal of Clinical Investigation|March 18, 2004
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyA Mehta, R Ricci, U Widmer, et al.
Clinical Genetics|March 18, 2004
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapyC Whybra, C Kampmann, F Krummenauer, et al.
Heart (British Cardiac Society)|May 18, 2000
Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central EuropeC Kampmann, C M Wiethoff, A Wenzel, et al.
European Journal of Clinical Investigation|December 21, 2004
Fabry disease: overall effects of agalsidase alfa treatmentM Beck, R Ricci, U Widmer, et al.
Journal of Internal Medicine|July 7, 2017
Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry diseaseM Lenders, D Oder, A Nowak, et al.
Pediatrics|November 11, 2009
Multidisciplinary management of Hunter syndromeJoseph Muenzer, M Beck, C M Eng, et al.
Journal of Inherited Metabolic Disease|June 7, 2012
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapyE Braunlin, H Rosenfeld, C Kampmann, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cardiovascular Surgery (London, England)|January 25, 2003
The Fontan-operation: from intra- to extracardiac procedureW Kuroczynski, C Kampmann, Y-H Choi, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 18, 2005
The right ventricle in Fabry diseaseC Kampmann, F A Baehner, C Whybra, et al.
Zeitschrift Fur Kardiologie|August 23, 2001
[Treatment of supravalvular pulmonary stenosis after arterial switch operations (ASO)]W Kuroczynski, C Kampmann, Y H Choi, et al.
European Journal of Clinical Investigation|March 18, 2004
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyA Mehta, R Ricci, U Widmer, et al.
Clinical Genetics|March 18, 2004
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapyC Whybra, C Kampmann, F Krummenauer, et al.
Heart (British Cardiac Society)|May 18, 2000
Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central EuropeC Kampmann, C M Wiethoff, A Wenzel, et al.
European Journal of Clinical Investigation|December 21, 2004
Fabry disease: overall effects of agalsidase alfa treatmentM Beck, R Ricci, U Widmer, et al.
Journal of Internal Medicine|July 7, 2017
Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry diseaseM Lenders, D Oder, A Nowak, et al.
Pediatrics|November 11, 2009
Multidisciplinary management of Hunter syndromeJoseph Muenzer, M Beck, C M Eng, et al.
Journal of Inherited Metabolic Disease|June 7, 2012
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapyE Braunlin, H Rosenfeld, C Kampmann, et al.
Pageof 6